Vertex Pharmaceuticals' Phase 3 Studies Offer Ample Opportunity For Upside
August 15, 2016 at 15:14 PM EDT
Leerink reiterated its Outperform rating on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) saying that Vx-661/Ivacaftor should drive ...
